Sweden
· Delayed Price · Currency is SEK Alligator Bioscience AB Company Description
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden.
The company’s product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage.
It also offers ALG.APV-527, a bispecific antibody that targets the 4-1BB and 5T4 molecules, which is in phase 1 clinical trial for the treatment of solid metastatic tumors; and ATOR-1017, an immunostimulatory antibody, which is in phase 1 clinical trial for the treatment of metastatic cancer.
In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; ALLIGATOR-FAB, which is built on multiple scaffolds with optimal drug development properties to further increase the structural diversity of generated antibodies; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format.
Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; MacroGenics, Inc.; Biotheus Inc.; BioArctic AB; and Abclon Inc. The company was founded in 2000 and is headquartered in Lund, Sweden.
| Country | Sweden |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Søren Bregenholt |
Contact Details
Address: Medicon Village Lund, 223 81 Sweden | |
| Phone | 46 4 65 40 82 00 |
| Website | alligatorbioscience.se |
Stock Details
| Ticker Symbol | ATORX |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0000767188 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Søren Bregenholt Ph.D. | Chief Executive Officer |
| Johan Gileus | Chief Financial Officer |
| Laura von Schantz | Chief Technology Officer |
| Dr. Peter Ellmark Ph.D. | Chief Scientific Officer |
| Greta Eklund | Investor Relations and Communications Manager |
| Dr. Sumeet Ambarkhane M.D. | Chief Medical Officer |